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Welcome to this special issue of PPAR Research dedicated
to “PPARs in Neuroinﬂammation.” The central nervous
system (CNS) was once thought to be an immune-privileged
site void of signiﬁcant inﬂammation. However, it is now
clear that activated peripheral immune cells are capable
or entering and functioning within the CNS. In addi-
tion, resident immune cells termed “microglia” protect the
CNS through production of molecules which are toxic to
pathogens. However, chronically activated microglia can
produce molecules toxic to host CNS cells, potentially
leading to neurodegeneration. Interestingly, a variety of
CNS disorders are characterized by neuroinﬂammation
and associated neurodegeneration. The role of PPARs in
modulating lipid and glucose metabolism is well established.
More recently, PPARs have been demonstrated to modulate
inﬂammation. For example, PPAR agonists inhibit the
production of proinﬂammatory molecules by peripheral
immune cells as well as resident CNS glia. Furthermore,
PPAR receptor agonists have proven eﬀective in suppressing
thedevelopmentofanimalmodelsofCNSinﬂammatoryand
neurodegenerative disorders. This suggests that modulation
of PPARs may be eﬀective in treating the related human
diseases.
This special issue of PPAR Research contains a series of
reviews concerning the role of PPARs in neuroinﬂammatory
diseases. We are fortunate to have received contributions
from experts in the ﬁelds concerning the potential role
of PPARs in modulating CNS disorders including multiple
sclerosis, Alzheimer’s disease, spinal cord injury, stroke,
traumatic brain injury, amyotrophic lateral sclerosis, and
Huntington’s disease. Also included are reviews concerning
the role of PPAR agonists in modulating the function of
resident CNS microglia, and the molecular mechanisms by
which PPARs regulate inﬂammatory signaling as related to
CNS disease.
We are pleased that this special issue of PPAR Research
also contains two original research reports. The ﬁrst report
provides a thorough investigation of the eﬀects of PPAR-γ
agonists in modulating the production of proinﬂammatory
molecules by CNS microglia and astrocytes in response to
distinct toll-like receptor ligands relevant to infections of
the CNS. The second report investigates PPAR-γ agonist
eﬀects on amyloid beta-mediated microglial production of
cytokines known to alter T-cell diﬀerentiation. This study
may have important implications concerning the use of
amyloid beta immunization for the treatment of Alzheimer’s
disease.
WehopethatyouﬁndthisspecialissueofPPARResearch
dedicated to PPARs in neuroinﬂammation to be informative,
and that the special issue will generate additional interest in
this rapidly evolving ﬁeld of research.
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